Peripheral and bone marrow CD34⁺ cell levels on chronic myeloproliferative disease

References

• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–951. doi: 10.1182/blood-2009-03-209262
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 world health organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14–22. doi: 10.1038/sj.leu.2404955
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an international prognostic score of thrombosis in world health organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128–5133. doi: 10.1182/blood-2012-07-444067
   PubMed Web of Science ®Google Scholar
• Passamonti F, Vanelli L, Malabarba E. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. Hematologica. 2003;88:1123–1129.
   PubMed Web of Science ®Google Scholar
• Arora B, Sirhan S, Hoyer JD. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. Br J Haematol. 2004;128:42–48. doi: 10.1111/j.1365-2141.2004.05280.x
   Web of Science ®Google Scholar
• Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000 Apr27;342(17):1255–1265. doi: 10.1056/NEJM200004273421706
   PubMed Web of Science ®Google Scholar
• Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol. 1999 Sep;17(9):2954–2970.
   PubMed Web of Science ®Google Scholar
• Barosi G, Ambrosetti A, Finelli C. The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. Br J Haematol. 1999 Mar;104(4):730–737. doi: 10.1046/j.1365-2141.1999.01262.x
   PubMed Web of Science ®Google Scholar
• Hibbin JA, Njoku OS, Matutes E, et al. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders. Br J Haematol. 1984 Jul;57(3):495–503. doi: 10.1111/j.1365-2141.1984.tb02924.x
   PubMed Web of Science ®Google Scholar
• Partanen S, Ruutu T, Vuopio P. Circulating haematopoietic progenitors in myelofibrosis. Scand J Haematol. 1982 Oct; 29(4):325–330. doi: 10.1111/j.1600-0609.1982.tb00602.x
   PubMedGoogle Scholar
• Le Bousse-Kerdiles MC, Martyre MC. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol. 1999 Oct;78(10):437–444. doi: 10.1007/s002770050595
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Czieslick C. Cd34 progenitor cells in idiopathic myelofibrosis a comparative quantification between spleen and bone marrow tissue. Ann Hematol. 2002 Feb;81(2):86–89. doi: 10.1007/s00277-001-0417-4
   PubMed Web of Science ®Google Scholar
• Wolf BC, Neiman RS. Hypothesis: splenic filtration and the pathogenesis of extramedullary hematopoiesis in agnogenic myeloid metaplasia. Hematol Pathol. 1987;1(1):77–80.
   PubMedGoogle Scholar
• Jäger R, Kralovics R. Molecular pathogenesis of Philadelphia chromosome negative chronic myeloproliferative neoplasms. Curr Cancer Drug Targets. 2011 Jan;11(1):20–30. doi: 10.2174/156800911793743628
   PubMed Web of Science ®Google Scholar
• Barosi G, Viarengo G, Pecci A. Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia. Blood. 2001;98:3249–3255. doi: 10.1182/blood.V98.12.3249
   PubMed Web of Science ®Google Scholar
• Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the world health organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international pert panel. Blood. 2007;110(4):1092–1097. doi: 10.1182/blood-2007-04-083501
   PubMed Web of Science ®Google Scholar
• Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88(6):507–516. doi: 10.1002/ajh.23417
   PubMedGoogle Scholar
• Finazzi G, Barbui T. Risk – Adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev. 2005;19:243–252. doi: 10.1016/j.blre.2005.01.001
   PubMed Web of Science ®Google Scholar
• Tefferi A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(9):915–925. doi: 10.1002/ajh.23703
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood. 2009;113(13):2895–2901. doi: 10.1182/blood-2008-07-170449
   PubMed Web of Science ®Google Scholar
• Malabarba E. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. Hematologica. 2003;88 (10):1123–1129.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Diehl V. Bone marrow CD34+ progenitor cells in Philadelphia chromosome-negative chronic myeloproliferative disorders–A clinicopathological study on 575 patients. Leuk Lymphoma. 2005 May;46(5):709–15. doi: 10.1080/10428190500046554
   PubMed Web of Science ®Google Scholar
• Emanuel RM1, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012 Nov;30(33):4098–4103. doi: 10.1200/JCO.2012.42.3863
   PubMed Web of Science ®Google Scholar
• Michiels JJ, Berneman Z, Van Bockstaele D, et al. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost. 2006 Apr;32(3):174–207. doi: 10.1055/s-2006-939431
   PubMed Web of Science ®Google Scholar
• Barbui T1, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013 Sep;122(13):2176–2184. doi: 10.1182/blood-2013-03-460154
   PubMed Web of Science ®Google Scholar
• Marchioli R1, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005 Apr;23(10):2224–2232. doi: 10.1200/JCO.2005.07.062
   PubMed Web of Science ®Google Scholar
• Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011 Jun;117(22):5857–5859. doi: 10.1182/blood-2011-02-339002
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM. CD34+ stem cells in chronic myeloproliferative disorders. Histol Histopathol. 2002 Apr;17(2):507–521.
   PubMed Web of Science ®Google Scholar
• Wang X, Prakash S, Lu M, et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest. 2012 Nov;122(11):3888–3899. doi: 10.1172/JCI64397
   PubMed Web of Science ®Google Scholar
• Wang X, Ye F, Tripodi J, et al. JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Blood. 2014 Nov;124(19):2987–2995. doi: 10.1182/blood-2014-02-558015
   PubMed Web of Science ®Google Scholar